ltp001
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 6, 2021 (NCT05135000)
Timeline
Indications
Mechanism of action
STAT3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06649110 | Phase 1/Phase 2 (Phase 2) | Oct 21, 2024 | Novartis |
| NCT05764265 | Phase 2 | Mar 27, 2023 | Novartis |
| NCT05497284 | Phase 2 | Nov 10, 2022 | Novartis |
| NCT05135000 | Phase 2 | Dec 6, 2021 | Novartis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 4 | 4 | 1 | 2021 |
1 organizations
Page 1 / 1